Two ACR 2025 analyses link SGLT2 inhibitors to fewer RA flares and a lower risk for osteoarthritis than GLP-1 receptor agonists, though randomized trials are still needed.
Medscape News Europe
Source link : https://www.medscape.com/viewarticle/could-sglt2-inhibitors-reduce-rheumatoid-arthritis-flares-2025a1000xvs?src=rss
Author :
Publish date : 2025-12-03 13:35:00
Copyright for syndicated content belongs to the linked Source.
